A 62-year-old woman with a 35 pack-year smoking history presents with a 2-month history of progressive dyspnea, hemoptysis, and right-sided chest pain. She also reports new-onset hoarseness and difficulty swallowing. Chest CT shows a 3.5 cm left hilar mass with invasion into the left main bronchus and mediastinal lymphadenopathy (station 4L and 7). Bronchoscopy with biopsy confirms small cell lung cancer. Which TNM stage and treatment approach is most appropriate?

Question

Accepted Answer

B. Stage IIIA; concurrent chemoradiotherapy (concurrent CRT) with platinum-etoposide. ## TNM Staging & SCLC Classification

This patient has **locally advanced SCLC** (Stage IIIA) based on:
- **T3** tumor (invasion into main bronchus)
- **N2** disease (ipsilateral mediastinal lymph node involvement, stations 4L and 7)
- **M0** (no distant metastases documented)

**Key Point:** SCLC staging in clinical practice often uses the **two-tier Veterans Administration Lung Study Group (VALSG) classification**:
- **Limited-stage disease (LD-SCLC):** Tumor confined to one hemithorax and regional lymph nodes (TNM stages I–IIIA)
- **Extensive-stage disease (ED-SCLC):** Distant metastases or contralateral involvement (TNM stage IIIB–IV)

This patient has **limited-stage disease** (T3N2M0 = Stage IIIA).

## Treatment Algorithm for LD-SCLC

```mermaid
flowchart TD
  A[Limited-Stage SCLC]:::outcome --> B{Performance Status 0-1?}:::decision
  B -->|Yes| C[Concurrent Chemoradiotherapy]:::action
  B -->|No| D[Sequential CRT or Palliative Tx]:::action
  C --> E[Platinum-Etoposide x 4-6 cycles]:::action
  E --> F[Concurrent Thoracic RT 45 Gy/30 fx]:::action
  F --> G[Prophylactic Cranial Irradiation if CR]:::action
  G --> H[Median OS 20-24 months]:::outcome
  D --> I[Chemotherapy first, then RT]:::action
  I --> J[Median OS 12-15 months]:::outcome
```

## Standard Treatment Regimen

**High-Yield:** The **gold standard for LD-SCLC** is:
1. **Concurrent chemoradiotherapy (concurrent CRT)** — superior to sequential CRT
   - **Chemotherapy:** Cisplatin 60 mg/m² day 1 + Etoposide 120 mg/m² days 1–3, repeated every 3 weeks × 4–6 cycles
   - **Thoracic radiotherapy:** 45 Gy in 30 fractions (1.5 Gy twice daily), starting with cycle 1 or 2
2. **Prophylactic cranial irradiation (PCI):** 25 Gy in 10 fractions if complete response (CR) achieved
   - Reduces brain metastasis incidence from ~40% to ~15%
   - Improves 2-year overall survival by ~5%

**Clinical Pearl:** Concurrent CRT achieves:
- **Complete response rate:** 50–60%
- **Median overall survival:** 20–24 months (vs. 12–15 months with sequential CRT)
- **2-year survival:** ~30–35%

## Why Concurrent CRT?

| Feature | Concurrent CRT | Sequential CRT |
|---------|---|---|
| **Median OS** | 20–24 months | 12–15 months |
| **2-yr survival** | 30–35% | 15–20% |
| **Toxicity** | Higher (esophagitis, pneumonitis) | Lower |
| **Compliance** | Demanding (6–8 weeks) | More flexible |
| **Indication** | PS 0–1, LD-SCLC | PS ≥2 or poor tolerance |

**Mnemonic: LD-SCLC Treatment** — **"Concurrent Chemo-RT + PCI"** — Limited-stage SCLC is curable with aggressive concurrent therapy; always add PCI if CR achieved.

[cite:Harrison 21e Ch 297; Robbins 10e Ch 15]

![Lung Cancer — Small Cell diagram](https://mmcphlazjonnzmdysowq.supabase.co/storage/v1/object/public/blog-images/explanation/3513.webp)

Answer

A. Stage IV; palliative chemotherapy with best supportive care

Answer

C. Stage IIB; chemotherapy alone (platinum-etoposide) followed by observation

Answer

D. Stage IIIB; sequential chemoradiotherapy (chemotherapy first, then radiotherapy)

Explanation

TNM Staging & SCLC Classification

Treatment Algorithm for LD-SCLC

Standard Treatment Regimen

Why Concurrent CRT?

Practice similar questions

Join our NEET PG community

Feature	Concurrent CRT	Sequential CRT
Median OS	20–24 months	12–15 months
2-yr survival	30–35%	15–20%
Toxicity	Higher (esophagitis, pneumonitis)	Lower
Compliance	Demanding (6–8 weeks)	More flexible
Indication	PS 0–1, LD-SCLC	PS ≥2 or poor tolerance